![]() |
市場調查報告書
商品編碼
2088998
眼科超音波診斷設備市場:2026-2032年全球市場預測(按設備類型、探頭類型、模式、便攜性、應用、最終用戶和分銷管道分類)Ophthalmic Ultrasound Devices Market by Device Type, Probe Type, Modality, Portability, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,眼科超音波診斷設備市場規模將達到 1,497,830,000 美元,複合年成長率為 9.90%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 7.7324億美元 |
| 預計年份:2026年 | 8.5028億美元 |
| 預測年份 2032 | 1,497,830,000 美元 |
| 複合年成長率 (%) | 9.90% |
眼科超音波設備在視網膜、白內障、青光眼、眼外傷、腫瘤和眼前節治療等領域仍是不可或缺的診斷和手術規劃工具。當嚴重白內障、角膜混濁、玻璃體出血或其他阻塞導致光學成像受限時,則可採用A超生物測量、B超、超音波超音波和射頻探頭等技術。
超音波領域正從獨立、依賴操作者的診斷系統轉變為網路連接、結構緊湊、工作流程整合的平台。眼科醫護人員優先考慮那些集高解析度成像、直覺式介面、數位影像儲存功能以及與電子健康記錄整合於一體的設備,以提高診斷準確性並縮短就診時間。
人工智慧正透過影像最佳化、自動結構檢測、測量輔助和決策支援工作流程,開始影響眼科超音波領域。雖然視網膜眼底影像和光學同調斷層掃描(OCT) 的臨床應用更為成熟,但同樣的資料科學原理也正被應用於超音波資料集,以提高掃描品質、減少觀察的變異性並加快分流速度。
由於亞太地區患者群體龐大、人口老化、白內障手術候診名單不斷延長,以及中國、印度、日本、韓國、澳洲和東協市場眼科醫療基礎設施的不斷完善,該地區正成為重點關注區域。該地區既有先進的三級眼科中心,也有醫療資源匱乏的農村地區,因此對高階眼科成像系統和攜帶式、經濟實惠的超音波平台的需求日益成長。
在東協市場,隨著各國政府加大對全民健康覆蓋(UHC)、白內障手術計畫和地方醫院現代化建設的投入,超音波診斷設備的重要性日益凸顯。市場需求集中在耐用且易於使用的超音波診斷設備既可用於都市區眼科中心,也可用於鄉村診所。在海灣合作理事會(GCC)國家,受專科醫院投資、人均醫療保健支出高企以及私立眼科連鎖機構發展壯大的推動,高階診斷平台的需求也在不斷成長。
美國憑藉其先進的視網膜治療技術、大量的白內障手術、完善的門診手術中心以及在FDA監管下健全的醫療技術生態系統,引領著高價值產品的普及。加拿大則透過醫院眼科診療和省級政府採購,實現了穩定的需求。另一方面,墨西哥受益於私人眼科機構的擴張和跨境醫療服務的趨勢。巴西憑藉其龐大的人口規模和不斷成長的眼科專科診所網路,仍然是拉丁美洲最大的市場機會所在。
產業領導者應優先考慮兼顧卓越圖像品質、便攜性、價格優勢和易用性的產品系列。製造商可透過將A型掃描、B型掃描、超音波顯微鏡和生物辨識功能與直覺的軟體、雲端資料管理和強大的網路安全措施相結合,來增強其競爭優勢。
本執行摘要採用以二手檢驗為中心的三角驗證方法編寫,該方法交叉引用了公共衛生統計數據、醫療設備監管資訊來源、眼科臨床指南和同行評審文獻。主要參考文獻包括世界衛生組織 (WHO)、國際防盲機構 (IAPB)、各國衛生組織、美國食品藥物管理局(FDA)、歐洲醫療設備法規結構、以及已發表的眼科影像學研究。
隨著眼科醫療專業人員應對白內障、視網膜疾病、眼外傷、青光眼和眼腫瘤病例的不斷增加,眼科超音波診斷設備市場預計將繼續保持其重要性。儘管光學成像技術取得了進步,但在因不透明介質、緊急情況或眼部深層結構而導致能見度受限時,超音波診斷仍然是必不可少的工具。
The Ophthalmic Ultrasound Devices Market is projected to grow by USD 1,497.83 million at a CAGR of 9.90% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 773.24 million |
| Estimated Year [2026] | USD 850.28 million |
| Forecast Year [2032] | USD 1,497.83 million |
| CAGR (%) | 9.90% |
Ophthalmic ultrasound devices remain essential diagnostic and surgical-planning tools across retina, cataract, glaucoma, trauma, oncology, and anterior-segment care. A-scan biometry, B-scan ultrasonography, ultrasound biomicroscopy, and high-frequency probes are used when optical imaging is limited by dense cataract, corneal opacity, vitreous hemorrhage, or other media obstruction.
Demand is supported by the rising burden of eye disease and avoidable vision impairment. The World Health Organization reports that at least 2.2 billion people globally have near or distance vision impairment, while population aging continues to expand the pool of patients requiring cataract evaluation, intraocular lens power calculation, retinal assessment, and ocular tumor monitoring. As health systems emphasize earlier diagnosis and procedure efficiency, ophthalmic ultrasound devices are increasingly valued for portability, repeatability, and use in both hospital and ambulatory eye-care settings.
The ophthalmic ultrasound landscape is shifting from stand-alone, operator-dependent diagnostic systems toward connected, compact, and workflow-integrated platforms. Eye-care providers are prioritizing devices that combine high-resolution imaging, intuitive interfaces, digital image storage, and electronic health record connectivity to improve diagnostic confidence and reduce appointment time.
A second shift is the broadening of care locations. Portable B-scan systems and compact biometry platforms are enabling deployment in ambulatory surgery centers, community eye clinics, emergency departments, and outreach programs. This is particularly important where optical coherence tomography or advanced retinal imaging is unavailable or less effective due to media opacity. At the same time, regulatory expectations around device safety, cybersecurity, software validation, and traceable measurement accuracy are raising the bar for manufacturers competing in premium ophthalmic diagnostics.
Artificial intelligence is beginning to influence ophthalmic ultrasound through image optimization, automated structure detection, measurement assistance, and decision-support workflows. While clinical adoption remains more mature in retinal fundus imaging and optical coherence tomography, the same data-science principles are being applied to ultrasound datasets to improve scan quality, reduce interpretation variability, and accelerate triage.
The cumulative impact of AI is expected to be strongest where ophthalmic ultrasound requires skilled acquisition and interpretation, including vitreoretinal pathology, ocular trauma, posterior segment evaluation behind dense cataracts, and anterior-segment measurements. AI-enabled tools can support less-experienced operators by flagging poor image quality, assisting with caliper placement, and standardizing longitudinal comparisons. However, adoption depends on validated clinical performance, representative training data, transparent regulatory clearance, and integration with ophthalmology workflows rather than stand-alone algorithm performance.
Asia-Pacific is becoming a high-priority region due to large patient volumes, aging populations, cataract backlogs, and expanding ophthalmology infrastructure in China, India, Japan, South Korea, Australia, and ASEAN markets. The region's mix of advanced tertiary eye centers and underserved rural communities increases demand for both premium ocular imaging systems and portable, cost-efficient ophthalmic ultrasound platforms.
North America benefits from strong reimbursement structures, advanced ambulatory surgery networks, FDA-cleared device pathways, and a high concentration of ophthalmologists and retina specialists. Europe is shaped by CE-mark requirements, public health procurement, and strong clinical adoption in Germany, France, Italy, Spain, and the United Kingdom. Latin America shows steady opportunity through Brazil and Mexico as private eye-care networks expand and cataract care access improves. The Middle East, particularly GCC countries, is investing in specialty hospitals and medical tourism, while Africa's opportunity is closely tied to portable diagnostics, NGO-supported vision programs, and capacity building in ophthalmic training.
ASEAN markets are gaining relevance as governments invest in universal health coverage, cataract surgery programs, and regional hospital modernization. Demand favors durable, easy-to-use ultrasound devices that can serve both urban eye centers and provincial clinics. GCC countries are positioned toward premium diagnostic platforms, driven by specialty hospital investment, high per-capita health expenditure, and growth in private ophthalmology chains.
The European Union remains influential through harmonized medical device regulation, evidence-driven procurement, and clinical research networks. BRICS markets collectively represent substantial patient volume, led by China, India, and Brazil, although price sensitivity and local manufacturing policies shape purchasing decisions. G7 countries continue to drive high-end innovation, regulatory benchmarks, and adoption of connected diagnostics. NATO member markets overlap with many advanced healthcare systems where cybersecurity, supply resilience, and interoperable digital infrastructure increasingly influence ophthalmic device procurement.
The United States leads high-value adoption through advanced retina care, cataract surgery volumes, ambulatory surgery centers, and a strong FDA-regulated medtech ecosystem. Canada shows stable demand through hospital-based ophthalmology and provincial procurement, while Mexico benefits from expanding private eye-care providers and cross-border medical service dynamics. Brazil remains Latin America's largest opportunity due to population scale and growth in specialty ophthalmology networks.
In Europe, the United Kingdom, Germany, France, Italy, and Spain support demand through established cataract and retinal care pathways, while Russia's market is influenced by localized procurement and import constraints. China and India represent large-scale growth opportunities driven by cataract burden, diabetic eye disease, and expanding eye hospital chains. Japan, South Korea, and Australia emphasize advanced technology adoption, quality standards, and specialist-led care, making them attractive markets for high-resolution, workflow-connected ophthalmic ultrasound systems.
Industry leaders should prioritize product portfolios that balance premium image quality with portability, affordability, and ease of use. Manufacturers can strengthen competitiveness by combining A-scan, B-scan, ultrasound biomicroscopy, and biometry capabilities with intuitive software, cloud-enabled data management, and robust cybersecurity controls.
Commercial teams should align strategies with site-of-care expansion, especially ambulatory surgery centers, emergency ophthalmology, and community eye screening programs. Evidence generation is critical: companies should invest in clinical validation, peer-reviewed performance data, and workflow studies that demonstrate faster diagnosis, improved measurement repeatability, and reduced operator variability. Partnerships with eye hospitals, training institutes, and teleophthalmology providers can accelerate adoption in emerging markets while supporting responsible AI integration and post-market surveillance.
This executive summary is developed using a secondary-research-led methodology supported by triangulation across public health statistics, medical device regulatory sources, ophthalmology clinical guidance, and peer-reviewed literature. Key reference points include the World Health Organization, International Agency for the Prevention of Blindness, national health agencies, FDA and European medical device frameworks, and published ophthalmic imaging research.
Market interpretation considers disease burden, procedure volumes, technology adoption, healthcare infrastructure, procurement models, reimbursement conditions, and regional regulatory environments. Insights are validated through cross-comparison of multiple reputable sources to avoid reliance on a single dataset. The methodology emphasizes factual accuracy, and industry relevance around ophthalmic ultrasound devices, A-scan biometry, B-scan ultrasound, ultrasound biomicroscopy, ocular imaging, and ophthalmology diagnostics.
The ophthalmic ultrasound devices market is positioned for sustained relevance as eye-care providers manage rising cataract, retinal, trauma, glaucoma, and ocular oncology workloads. Even as optical imaging technologies advance, ultrasound remains indispensable when opaque media, emergency conditions, or deep ocular structures limit visualization.
Future development will be shaped by portable device adoption, workflow integration, AI-assisted imaging, and demand from high-volume emerging markets. Organizations that deliver clinically validated, connected, and user-friendly ophthalmic ultrasound solutions will be best positioned to serve both advanced specialty centers and underserved care settings. The strongest competitive advantage will come from combining diagnostic reliability with efficient deployment across increasingly decentralized ophthalmology care models.